SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival
Purpose: Up to 30-40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time range of 2-10 years. This is in part caused by the absence of prognostic biomarkers that can identify high-risk patients to assign them to risk-adapted monitoring and t...
Saved in:
Published in | bioRxiv |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Paper |
Language | English |
Published |
Cold Spring Harbor
Cold Spring Harbor Laboratory Press
17.12.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: Up to 30-40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time range of 2-10 years. This is in part caused by the absence of prognostic biomarkers that can identify high-risk patients to assign them to risk-adapted monitoring and treatment regimens. Since cancer stemness has been associated with tumor relapse and poor outcome, we investigated in the current study the prognostic potential SOX2 (sex determining region Y box 2) - a major transcription factor involved in development and stemness - previously described to contribute to the undifferentiated phenotype of EwS. Methods: Two independent patient cohorts, one consisting of 189 retrospectively collected EwS tumors with corresponding mRNA expression data (test cohort) and the other of 141 prospectively collected formalin-fixed and paraffin embedded resected tumors (validation cohort), were employed to analyze SOX2 expression levels by DNA microarrays or immunohistochemistry, respectively, and to compare them with clinical parameters and patient outcome. Two methods were employed to test the validity of the results at both mRNA and protein levels. Results: Both cohorts showed that only a subset of EwS patients (16-20%) express high SOX2 mRNA or protein levels, which significantly correlated with poor overall survival. Multivariate analyses of our validation cohort revealed that high SOX2 expression represents a major risk factor for survival (HR=3.19; P<0.01) that is independent from metastasis and other known clinical risk-factors at time of diagnosis. Univariate analysis demonstrated that SOX2-high expression correlated with tumor relapse (P=0.001). Median first relapse was at 14.7 months (range: 3.5-180.7). Conclusions: High SOX2 expression constitutes an independent prognostic biomarker for EwS patients with poor outcome, which may help to identify patients with localized disease who are at high risk for tumor relapse within the first two years after diagnosis. |
---|---|
AbstractList | Purpose: Up to 30-40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time range of 2-10 years. This is in part caused by the absence of prognostic biomarkers that can identify high-risk patients to assign them to risk-adapted monitoring and treatment regimens. Since cancer stemness has been associated with tumor relapse and poor outcome, we investigated in the current study the prognostic potential SOX2 (sex determining region Y box 2) - a major transcription factor involved in development and stemness - previously described to contribute to the undifferentiated phenotype of EwS. Methods: Two independent patient cohorts, one consisting of 189 retrospectively collected EwS tumors with corresponding mRNA expression data (test cohort) and the other of 141 prospectively collected formalin-fixed and paraffin embedded resected tumors (validation cohort), were employed to analyze SOX2 expression levels by DNA microarrays or immunohistochemistry, respectively, and to compare them with clinical parameters and patient outcome. Two methods were employed to test the validity of the results at both mRNA and protein levels. Results: Both cohorts showed that only a subset of EwS patients (16-20%) express high SOX2 mRNA or protein levels, which significantly correlated with poor overall survival. Multivariate analyses of our validation cohort revealed that high SOX2 expression represents a major risk factor for survival (HR=3.19; P<0.01) that is independent from metastasis and other known clinical risk-factors at time of diagnosis. Univariate analysis demonstrated that SOX2-high expression correlated with tumor relapse (P=0.001). Median first relapse was at 14.7 months (range: 3.5-180.7). Conclusions: High SOX2 expression constitutes an independent prognostic biomarker for EwS patients with poor outcome, which may help to identify patients with localized disease who are at high risk for tumor relapse within the first two years after diagnosis. |
Author | Sannino, Giuseppina Gerke, Julia S Ranft, Andreas Jabar, Susanne Stein, Stefanie Zacherl, Constanze Musa, Julian Orth, Martin F Ohmura, Shunya Hardiman, Gary Wehweck, Fabienne S Sastre, Ana Knott, Maximilian M L Kiran, Merve M Dirksen, Uta Hoelting, Tilman L B Cidre-Aranaz, Florencia Li, Jing Grunewald, Thomas G P Marchetto, Aruna Romero-Perez, Laura Juergens, Heribert Alonso, Javier Wilian Da Silveira Kirchner, Thomas Alba-Rubio, Rebeca Hartmann, Wolfgang |
Author_xml | – sequence: 1 givenname: Giuseppina surname: Sannino fullname: Sannino, Giuseppina – sequence: 2 givenname: Aruna surname: Marchetto fullname: Marchetto, Aruna – sequence: 3 givenname: Andreas surname: Ranft fullname: Ranft, Andreas – sequence: 4 givenname: Susanne surname: Jabar fullname: Jabar, Susanne – sequence: 5 givenname: Constanze surname: Zacherl fullname: Zacherl, Constanze – sequence: 6 givenname: Rebeca surname: Alba-Rubio fullname: Alba-Rubio, Rebeca – sequence: 7 givenname: Stefanie surname: Stein fullname: Stein, Stefanie – sequence: 8 givenname: Fabienne surname: Wehweck middlename: S fullname: Wehweck, Fabienne S – sequence: 9 givenname: Merve surname: Kiran middlename: M fullname: Kiran, Merve M – sequence: 10 givenname: Tilman surname: Hoelting middlename: L B fullname: Hoelting, Tilman L B – sequence: 11 givenname: Julian surname: Musa fullname: Musa, Julian – sequence: 12 givenname: Laura surname: Romero-Perez fullname: Romero-Perez, Laura – sequence: 13 givenname: Florencia surname: Cidre-Aranaz fullname: Cidre-Aranaz, Florencia – sequence: 14 givenname: Maximilian surname: Knott middlename: M L fullname: Knott, Maximilian M L – sequence: 15 givenname: Jing surname: Li fullname: Li, Jing – sequence: 16 givenname: Heribert surname: Juergens fullname: Juergens, Heribert – sequence: 17 givenname: Ana surname: Sastre fullname: Sastre, Ana – sequence: 18 givenname: Javier surname: Alonso fullname: Alonso, Javier – sequence: 19 fullname: Wilian Da Silveira – sequence: 20 givenname: Gary surname: Hardiman fullname: Hardiman, Gary – sequence: 21 givenname: Julia surname: Gerke middlename: S fullname: Gerke, Julia S – sequence: 22 givenname: Martin surname: Orth middlename: F fullname: Orth, Martin F – sequence: 23 givenname: Wolfgang surname: Hartmann fullname: Hartmann, Wolfgang – sequence: 24 givenname: Thomas surname: Kirchner fullname: Kirchner, Thomas – sequence: 25 givenname: Shunya surname: Ohmura fullname: Ohmura, Shunya – sequence: 26 givenname: Uta surname: Dirksen fullname: Dirksen, Uta – sequence: 27 givenname: Thomas surname: Grunewald middlename: G P fullname: Grunewald, Thomas G P |
BookMark | eNotjT9PwzAUxD3AAAU-w5OYC7Zf7NQjqsofqVIHOrBVJnluDKlt7KTl4xOpLHfS_XR31-wixECM3Qn-IAQXj5VZSIVXrH3ffEig35SpFB8D-JbC4J2nAquTD3soNjfxYCHZwU-owMkPHXR-30H25RtczDCMh0kz9TYVAhtaSHEKypiP_mj7G3bpbF_o9t9nbPu82i5f5-vNy9vyaT1PmuOcWinQ1lo4biQ6QtFQS2Qs1kpr1ChMo00tpXaW9NRoBCKv-KeqeO0ahTN2f55NOf6MVIbdVxxzmB53UqhaGykWCv8AOapQww |
ContentType | Paper |
Copyright | 2018. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2018. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 8FE 8FH AAFGM AAMXL ABOIG ABUWG ADZZV AFKRA AFLLJ AFOLM AGAJT AQTIP AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PIMPY PQCXX PQEST PQQKQ PQUKI PRINS |
DOI | 10.1101/498253 |
DatabaseName | ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central Korea - hybrid linking Natural Science Collection - hybrid linking Biological Science Collection - hybrid linking ProQuest Central (Alumni) ProQuest Central (Alumni) - hybrid linking ProQuest Central SciTech Premium Collection - hybrid linking ProQuest Central Student - hybrid linking ProQuest Central Essentials - hybrid linking ProQuest Women's & Gender Studies - hybrid linking ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database Publicly Available Content Database ProQuest Central - hybrid linking ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China |
DatabaseTitle | Publicly Available Content Database ProQuest Central Student ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest One Academic |
DatabaseTitleList | Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Genre | Working Paper/Pre-Print |
GroupedDBID | 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PIMPY PQEST PQQKQ PQUKI PRINS |
ID | FETCH-LOGICAL-p603-ed213a761f0923fe31cedee9a3756636319c697226fae6603c133040b5407fc53 |
IEDL.DBID | BENPR |
IngestDate | Fri Sep 13 07:05:01 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-p603-ed213a761f0923fe31cedee9a3756636319c697226fae6603c133040b5407fc53 |
OpenAccessLink | https://www.proquest.com/docview/2157692185/abstract/?pq-origsite=%requestingapplication% |
PQID | 2157692185 |
PQPubID | 2050091 |
ParticipantIDs | proquest_journals_2157692185 |
PublicationCentury | 2000 |
PublicationDate | 20181217 |
PublicationDateYYYYMMDD | 2018-12-17 |
PublicationDate_xml | – month: 12 year: 2018 text: 20181217 day: 17 |
PublicationDecade | 2010 |
PublicationPlace | Cold Spring Harbor |
PublicationPlace_xml | – name: Cold Spring Harbor |
PublicationTitle | bioRxiv |
PublicationYear | 2018 |
Publisher | Cold Spring Harbor Laboratory Press |
Publisher_xml | – name: Cold Spring Harbor Laboratory Press |
Score | 1.584965 |
Snippet | Purpose: Up to 30-40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time range of 2-10 years. This... |
SourceID | proquest |
SourceType | Aggregation Database |
SubjectTerms | Biomarkers Diagnosis DNA microarrays Ewing's sarcoma Gene expression Immunohistochemistry Metastases Metastasis Paraffin Patients Phenotypes Risk groups Survival Tumors |
Title | SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival |
URI | https://www.proquest.com/docview/2157692185/abstract/ |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV07T8MwELZKs7CBAPEoyAOrlYdjB09IoFQVEqWCInWr_LhIDE1Ck4r-fM7FFQMSi4dYWc7n-z5_Pt8RcptxVwhjNTOQcZY7WTFteMKExtV3wJXbabrPUzl5z58WYjEgk_1bGJ9WuY-Ju0DtGus18hihqZAKAUnE2ngVwPbxffvJfP8of88ammkckChLc39hGz2U09lraCeEjhfnCk9D_E_M3QHJ-IhEM93C-pgMoD4h7u1lkVHYhmTUmn64n-Qd6Gj5haBCO_TDZqVpKH_aUa-bUl9jmPqkcIqUk_abFY7-UUrbAdW1o22DH7oNRgH0o1MyH5fzxwkLbQ9YKxPOwGUp14VMqwTJVwU8teAAlOYFUi8ucc9YqQqkTZUGiX_Y1GsSifGl9Cor-BkZ1k0N54Rao0RlwWqDhy7ljJYGEq6Mk9rhIokLMtrbYhlct1v-Gvry_-krcojs4c7ndqTFiAz79QauEaF7cxOM_w0XnJbR |
link.rule.ids | 786,790,21416,27958,33779,43840 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwELWgHWADAeKjgAdWq0kcO3hCArUq0JYKitSt8sdFYiAJdSv4-ZyLKwYklgyOsvjO9-6eX-4Iucq4K4SxmhnIOMudLJk2PGFCo_UdcOXWnO5oLAev-cNMzCLh5qOschMT14Ha1TZw5F2EpkIqBCRx03ywMDUq3K7GERrbpJ1zLFVapH3bG0-e4xAhdLdurrAG4n8i7Ro--nukPdENLPbJFlQHxL08zTIKX1GCWtE39yPZAU97nwgl1KP31e-axqannga2lIbOwjRIwSkmmnS5esdn-BWl8UB15WhT44Jf4dlH7zkk035vejdgcdgBa2TCGbgs5bqQaZlgylUCTy04AKV5gQkXl3hSrFQFJkulBolf2DQwEYkJDfRKK_gRaVV1BceEWqNEacFqg6WWckZLAwlXxknt0DTihHQ2ezGPDuvnv9t7-v_rS7IzmI6G8-H9-PGM7GL-cB3UHWnRIa3lYgXniNFLcxEN8Q3mdJYE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SOX2+expression+identifies+Ewing+sarcoma+patients+with+high+risk+for+tumor+relapse+and+poor+survival&rft.jtitle=bioRxiv&rft.au=Sannino%2C+Giuseppina&rft.au=Marchetto%2C+Aruna&rft.au=Ranft%2C+Andreas&rft.au=Jabar%2C+Susanne&rft.date=2018-12-17&rft.pub=Cold+Spring+Harbor+Laboratory+Press&rft_id=info:doi/10.1101%2F498253 |